GlassScriptPhysician profile
Kimberly Joy Buck
NPI 1851680078
$2,998.70
in general payments reported to CMS, 2019-2025
20 companies · $737 in 2025
The $737 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $390 · 2023: $895 · 2024: $865 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.71 | 2022-2025 | |
| Rhythm Pharmaceuticals, INC. | $635.92 | 2022-2025 | Imcivree, Imcivree |
| Novo Nordisk INC | $298.86 | 2022-2025 | Wegovy, Sogroya |
| Tolmar, INC. | $263.12 | 2023-2025 | Fensolvi |
| Pfizer INC. | $161.30 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $142.77 | 2021-2024 | Strensiq |
| Sanofi-Aventis U.S. LLC | $132.01 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $113.08 | 2022-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tolmar Pharmaceuticals, INC. | $94.06 | 2021-2022 | |
| Phadia US INC. | $89.46 | 2021-2025 | Immunocap |
| Sobi, INC | $58.10 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $47.47 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $46.12 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi Pasteur INC. | $39.13 | 2023 | |
| Cranial Technologies, INC | $36.58 | 2023-2025 | Doc Band |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.12 | 2023 | Bexsero |
| Kyowa Kirin, INC. | $23.94 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $23.87 | 2023 | |
| Biomarin Pharmaceutical INC. | $23.00 | 2023 | Voxzogo 1.2mg |
| Eton Pharmaceuticals, INC. | $15.08 | 2023 | Alkindi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.